Evidence map›Paper›PMID 34668635›Full record

ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2022

Dual JAK2/Aurora kinase A inhibition prevents human skin graft rejection by allo-inactivation and ILC2-mediated tissue repair.

Kelly Walton, Kirsti Walker, Megan Riddle, Brent H Koehn, Jordan Reff, Elizabeth M Sagatys, Michael A Linden, Joseph Pidala, Jongphil Kim, Marie C Lee and 12 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 4 institutions in 1 country.

Kelly WaltonDivision of Hematology, Oncology, and Transplantation, Department of Medicine, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.
Kirsti WalkerDivision of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.
Megan RiddleDivision of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.
Brent H KoehnDivision of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.
Jordan ReffDepartment of Immunology, Moffitt Cancer Center, Tampa, Florida.
Elizabeth M SagatysDepartment of Immunology, Moffitt Cancer Center, Tampa, Florida.
Michael A LindenDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota.
Joseph PidalaDepartment of Immunology, Moffitt Cancer Center, Tampa, Florida.
Jongphil KimDepartment of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, Florida.
Marie C LeeDepartment of Oncologic Sciences, Moffitt Cancer Center, Tampa, Florida.
John V KilukDepartment of Oncologic Sciences, Moffitt Cancer Center, Tampa, Florida.
Jane Yuet Ching HuiDepartment of Surgery, University of Minnesota, Minneapolis, Minnesota.
Sang Y YunDepartment of Oncologic Sciences, Moffitt Cancer Center, Tampa, Florida.
Yan XingDivision of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.
Heather StefanskiDivision of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.
Harshani R LawrenceDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota.
Nicholas J LawrenceDepartment of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota.
Jakub TolarDivision of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.
Claudio AnasettiDepartment of Immunology, Moffitt Cancer Center, Tampa, Florida.
Bruce R BlazarDivision of Blood and Marrow Transplantation, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.
Said M SebtiDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia.
Brian C BettsDivision of Hematology, Oncology, and Transplantation, Department of Medicine, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0001-7643-2422
University of Minnesota Medical Center · USMoffitt Cancer Center · USUniversity of Minnesota · USVirginia Commonwealth University · US

Funding

TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI Christine O'Connell · 1998 to 2026
$93.5M
Trial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI J SUNIL RAO · 1995 to 2026
$48.2M
Enhancing Treg Therapeutic Efficacy in GVHDR01HL118979 · NHLBI · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, HIPPEN, KELI L · 2014 to 2025
$6.7M
T-CELL TARGETING FOR GVHDR01HL056067 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R · 1995 to 2022
$5.4M
In Vivo Prevention of Murine GVHDR37AI034495 · NIAID · UNIVERSITY OF MINNESOTA · PI Bruce R Blazar · 2017 to 2026
$5.4M
Nongenotoxic conditioning for gene therapy and allogeneic transplantation in Fanconi anemiaR01HL147324 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Bruce R Blazar, HANS-PETER KIEM · 2020 to 2026
$4.1M
Targeting T-cell costimulation and cytokine activation to prevent GVHD and preserve GVLR01HL133823 · NHLBI · UNIVERSITY OF MINNESOTA · PI BETTS, BRIAN C · 2016 to 2020
$2.2M
Developing Chemical Probes for Oncogenic Signaling PathwaysR50CA211447 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI Harshani R Lawrence · 2017 to 2026
$2.2M
NCI NIH HHS P01 CA065493NCI NIH HHS P30 CA076292NCI NIH HHS R50 CA211447NHLBI NIH HHS R01 HL056067NHLBI NIH HHS R01 HL11879NHLBI NIH HHS R01 HL118979NHLBI NIH HHS R01 HL133823NHLBI NIH HHS R01 HL147324NIAID NIH HHS R37 AI034495
6 · The paper itself

Abstract

Prevention of allograft rejection often requires lifelong immune suppression, risking broad impairment of host immunity. Nonselective inhibition of host T cell function increases recipient risk of opportunistic infections and secondary malignancies. Here we demonstrate that AJI-100, a dual inhibitor of JAK2 and Aurora kinase A, ameliorates skin graft rejection by human T cells and provides durable allo-inactivation. AJI-100 significantly reduces the frequency of skin-homing CLA

Indexed as

Aurora Kinase AImmunity, InnateAnimalsGraft RejectionHumansJanus Kinase 2MiceMice, Inbred C57BLTh17 CellsTransplantation, HomologousAurora Kinase AJAK2 protein, humanJanus Kinase 2basic (laboratory) research/sciencecostimulationcytokines/cytokine receptorsgraft survivalimmunobiologyimmunosuppressant-otherimmunosuppression/immune modulationinnate immunitytranslational research/sciencexenotransplantation

Identifiers

PMID34668635
PMCPMC8897228
OpenAlexW3205349002

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.